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Photodynamic Therapy–Induced Immunosuppression
in Humans Is Prevented by Reducing the Rate of Light
Delivery
Georgia A. Frost1, Gary M. Halliday1 and Diona L. Damian1
Photodynamic therapy (PDT) of non-melanoma skin cancers currently carries failure rates of 10–40%. The
optimal irradiation protocol is as yet unclear. Previous studies showed profound immunosuppression after PDT,
which may compromise immune-mediated clearance of these antigenic tumors. Slower irradiation prevents
immunosuppression in mice, and may be at least as effective as high-fluence-rate PDT in preliminary clinical
trials. The photosensitizers 5-aminolaevulinic acid and/or methyl aminolaevulinate were applied to discrete
areas on the backs of healthy Mantoux-positive volunteers, followed by narrowband red light irradiation
(632 nm) at varied doses and fluence rates. Delayed type hypersensitivity (Mantoux) reactions were elicited at
test sites and control sites to determine immunosuppression. Human ex vivo skin received low- and high-
fluence-rate PDT and was stained for oxidative DNA photolesions. PDT caused significant, dose-responsive
immunosuppression at high (75mWcm2) but not low (15 or 45mWcm2) fluence rates. DNA photolesions,
which may be a trigger for immunosuppression, were observed after high-fluence-rate PDT but not when light
was delivered more slowly. This study demonstrates that the current clinical PDT protocol (75mWcm2) is
highly immunosuppressive. Simply reducing the rate of irradiation, while maintaining the same light dose,
prevented immunosuppression and genetic damage and may have the potential to improve skin cancer
outcomes.
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INTRODUCTION
Photodynamic therapy (PDT) for skin cancer comprises
topical application of a photosensitizer, followed by irradia-
tion with visible light in the presence of oxygen. PDT with
systemic photosensitizers has been used to treat a range of
internal malignancies, including lung, brain, esophagus,
bladder, and head and neck cancers (Brown et al., 2004).
Topical PDT, using the photosensitizing heme precursors
5-aminolaevulinic acid (ALA) or methylaminolaevulinate
(MAL), is increasingly used to treat superficial basal cell
carcinoma (BCC), Bowen’s disease (squamous cell carcinoma
in situ), and premalignant actinic keratoses (Morton et al.,
2002). Compared with surgery, ALA/MAL-PDT offers excel-
lent functional and cosmetic outcomes and is a more
practical option for the treatment of superficial but large
diameter lesions, and for patients with large numbers of skin
cancers.
Although ALA/MAL-PDT clearance rates of 490% have
been found for smaller superficial BCCs (Haller et al., 2000),
reported long-term clearance rates for BCC typically range
fromB50–84% depending on lesion size and number of PDT
sessions (Szeimies, 2007). Clearance rates of B76% at 5
years have been reported after two PDT sessions for nodular
BCCs (Rhodes et al., 2007) and B80% at 12 months for
Bowen’s disease (Morton et al., 2006), whereas actinic
keratoses showed initial clearance of B75% and recurrence
of 20% at 12 months (Tschen et al., 2006). Hence, ALA/MAL-
PDT using currently recommended protocols carries rela-
tively high failure rates. Immune suppressed transplant
recipients show even higher PDT failure rates, reflecting the
key role of skin immunity in the resolution of these antigenic
tumors (Dragieva et al., 2004).
For ALA/MAL-PDT of skin cancers, a maximum fluence
rate of 200mWcm2 is recommended (Babilas et al., 2006),
however, there is no defined lower limit. At high-fluence
rates, more rapid oxygen consumption likely outstrips
the oxygen supply from surrounding blood vessels, whereas
at low-fluence rates, tissue oxygenation remains at levels
adequate for completion of the photodynamic process (Foster
et al., 1991). Murine studies have shown that lower-fluence
rates cause more efficient photobleaching and greater tissue
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damage by topical ALA-PDT (Robinson et al., 1998), and
yield better tumor kill after systemic PDT (Sitnik and
Henderson, 1998; Iinuma et al., 1999). Preliminary human
studies also suggest that ALA/MAL-PDT with lower-fluence
rates may be as or more effective than current protocols
(Langmack et al., 2001; Ericson et al., 2004; Cottrell et al.,
2008). PDT is highly immunosuppressive in mice (Elmets and
Bowen, 1986), with suggestion that this may be prevented
or even reversed by lowering fluence rates (Sitnik and
Henderson, 1998; Henderson et al., 2004). The immune
effects of varying PDT fluence rates in humans are as yet
unknown.
PDT is generally considered to have little carcinogenic risk
(Morton et al., 2008). There are, however, reports of malig-
nancies developing in ALA/MAL-PDT-treated fields (Wolf
et al., 1997; Varma et al., 2000). The oxidative photoproduct
8-hydroxy-20-deoxyguanosine (8oxoG) is a marker of DNA
damage that is observed after UVA and UVB irradiation
(Javeri et al., 2008). PDT induces 8oxoG in mice (Takahashi
et al., 2005) and DNA strand breaks in human fibroblasts
(Haylett et al., 2003), however, there are no reported studies
in human skin.
The Mantoux reaction, a T-cell-mediated delayed type
hypersensitivity response to intradermally injected tuber-
culin purified protein derivative (PPD), offers a practical
and ethical model of in vivo skin immunity (Damian and
Halliday, 2002). Using this model, we recently reported that
topical ALA/MAL-PDT, delivered at 78mWcm2, is highly
immunosuppressive in humans (Matthews and Damian,
2010). We now report that ALA/MAL-PDT at high but not
low-fluence rates is immunosuppressive and causes genera-
tion of 8oxoG lesions in humans.
RESULTS
High-fluence-rate MAL-PDT and ALA-PDT are immune
suppressive
Fifteen volunteers of Fitzpatrick’s skin types II and III
(Fitzpatrick, 1998; 8 men, 7 women, mean age 40 years,
range 23–65) had mirrored templates on each side of their
lower backs, which were treated with MAL, ALA, vehicle,
or no lotion. One side of the back was irradiated with
high-fluence-rate red light (fluence rate 75mWcm2, total
dose 37 J cm2), whereas the other side remained light
protected. MAL-PDT significantly suppressed Mantoux in-
duration (mean±SEM Ddiameter 3.1±0.7mm, P¼0.003,
n¼15; Figure 1a) corresponding to a 33% mean reduction in
diameter. MAL-PDT also suppressed erythema (Derythema
index (EI) 34.7±9.8 erythema units, P¼ 0.03, n¼15;
Figure 1b) equating to a 37% mean reduction in EI. Likewise,
ALA-PDT significantly suppressed Mantoux diameter (Ddia-
meter 3.6±0.5mm, Po0.001, Figure 1a) corresponding
to a 40% mean reduction in diameter. ALA-PDT EI was
suppressed (DEI 53.6±9.6 erythema units, Po0.001, Figure
1b) by 67% compared with control.
Neither photosensitizer caused immune suppression in the
absence of irradiation. Mantoux reactions at unirradiated,
MAL-treated sites did not differ from control Mantoux
reactions (Ddiameter 0.4±0.1mm, P¼0.08, Figure 1a; DEI
5.4±5.3 erythema units, P¼1.0, Figure 1b). Similarly, ALA
alone was not immunosuppressive (Ddiameter 0.4±0.1mm,
P¼0.07, Figure 1a; DEI 8.0±5.4 erythema units, P¼ 1.0,
Figure 1b). Sites receiving red light only did not show
suppression of Mantoux diameter or erythema compared with
unirradiated control sites (Figure 1). This was further
investigated in three men and seven women (skin types II
and III, mean age 40, range 26–74). At separate sites on the
back, these volunteers received red light only (75mWcm2)
with total doses of 37, 111, and 222 J cm2 (up to six times
the standard therapeutic light dose) and MAL-PDT as a
positive control (37 J cm2, 75mWcm2). Two additional
sites served as unirradiated controls. Red light did not
suppress Mantoux induration nor erythema at any dose
(Ddiameter 0.4±0.2mm, P¼ 0.4; 0.5±0.2mm, P¼ 0.3;
0.6±0.5mm, P¼1.0; and DEI 1.7±6.8, P¼1.0;
8.8±7.6, P¼1.0; 0.7±7.8 P¼1.0 erythema units for
37, 111, and 222 J cm2, respectively). Again, MAL-PDT
caused immunosuppression ofB20% in diameter (Ddiameter
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Figure 1. Photodynamic therapy (PDT; fluence rate 75mWcm2 and
total dose 37 J cm2) with either methyl aminolaevulinate (MAL) or
5-aminolaevulinic acid (ALA) is highly immune suppressive in humans. Red
light alone or with vehicle, or photosensitizer alone (no light) did not cause
immunosuppression. Mantoux diameter and erythema at each treatment
site was subtracted from that at the unirradiated control site to determine
immunosuppression (a, Ddiameter; b, DEI; Student’s paired t test, n¼15).
EI, erythemia index; VEH, vehicle.
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1.9±0.5, P¼ 0.02) and 17% in erythema (DEI 17.7±5.6,
P¼0.048), in these 10 volunteers.
MAL-PDT is immune suppressive at high but not low fluence
rates
Fifteen volunteers (skin types II and III, 7 men, 8 women,
mean age 39, range 26–74) had MAL-PDT administered to
each side of the lower back. On one side total doses of 10,
20, and 37 J cm2 were delivered at a high-fluence rate of
75mWcm2. These three doses were also delivered to
the contralateral back at a low-fluence rate of 15mWcm2.
Mantoux reactions at each site were compared with
unirradiated controls (no light, no MAL).
High-fluence-rate MAL-PDT significantly suppressed Man-
toux reactions at total light doses of 37 J cm2 (Ddiameter
2.9±0.6mm, P¼0.002; DEI 34.5±7.5 erythema units,
P¼0.002) and 20 J cm2 (Ddiameter 1.9±0.5mm,
P¼0.006; DEI 35.0±6.4 erythema units, P¼o0.001) but
not 10 J cm2 (Ddiameter 1.4±0.5mm, P¼0.24; DEI
23.3±9.7 erythema units, P¼0.15; Figure 2). MAL-PDT
delivered at a low-fluence rate (15mWcm2) did not,
however, suppress Mantoux reactions at any dose (37 J cm2
Ddiameter 0.2±0.4mm, P¼ 1.0; DEI 13.7±8.5 erythema
units, P¼ 0.7; 20 J cm2 Ddiameter 0.2±0.4mm, P¼ 1.0,
DEI 1.5±7.1 erythema units, P¼1.0; 10 J cm2 Ddiameter
0.1±0.4mm, P¼ 1.0, DEI 3.4±6.6 erythema units, P¼ 1.0;
Figure 2).
Delivery of 37 J cm2 at a fluence rate of 75mWcm2
takes B8minutes, hence, delivery of this dose at
15mWcm2 takes B40minutes, which is less feasible in
clinical practice. Fifteen additional volunteers (skin types II
and III, seven men, eight women, mean age 40, range 24–65)
were thus recruited to compare the immune effects of an
intermediate fluence rate (45mWcm2; irradiance time
13minutes) to irradiance at 75mWcm2. High-fluence
(75mWcm2) MAL-PDT was immunosuppressive in this
group of volunteers at a dose of 37 J cm2 (Ddiameter
1.8±0.5mm, P¼ 0.02; DEI 24.7±7.0 erythema units,
P¼0.02), but not at lower doses (20 J cm2 Ddiameter
1.1±0.4mm, P¼0.07, DEI 30.5±10.3 erythema units,
P¼0.05; 10 J cm2; Ddiameter 0.4±0.3mm, P¼0.1, DEI
16.9±6.5 erythema units, P¼0.11, Figure 3).
MAL-PDT delivered with a fluence rate of 45mWcm2
did not suppress Mantoux reactions at any total light
dose (37 J cm2 Ddiameter 0.6±0.5mm, P¼ 1.0, DEI
13.0±10.1 erythema units, P¼1.0; 20 J cm2 Ddiameter
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Figure 2. High-fluence-rate PDT (75mWcm2) with methyl aminolaev-
ulinate (MAL) caused significant, dose responsive suppression of Mantoux
reactions. In contrast, low-fluence-rate MAL-PDT (15mWcm2) was not
immune suppressive at any dose (a, Ddiameter; b, DEI; Student’s paired t-test,
n¼ 15). EI, erythemia index.
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Figure 3. High-fluence-rate PDT (75mWcm2) with methyl
aminolaevulinate (MAL) significantly suppressed both Mantoux diameter
and erythema with a total light dose of 37 J cm2 but not 10 or 20 J cm2.
Low-fluence rate MAL-PDT (45mWcm2) was not immunosuppressive at any
dose (a, Ddiameter; b, DEI; Student’s paired t-test, n¼ 15). EI, erythemia
index.
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0.6±0.3mm, P¼0.4, DEI 16.3±6.3 erythema units,
P¼1.0; 10 J cm2 Ddiameter –0.6±0.3mm, P¼ 0.6, DEI
8.0±7.5 erythema units, P¼ 1.0, Figure 3).
PDT does not cause systemic immunosuppression
Systemic immunosuppression was determined by comparing
initial Mantoux reactions (measured 3 days before PDT) to
unirradiated control Mantoux reactions following PDT. There
was no significant difference in Mantoux-induced indu-
ration nor erythema before and after PDT in any group of
volunteers.
MAL-PDT induces 8oxoG at high but not low fluence rates
Three women (skin types II, III, and IV, mean age 37 years,
range 29–45) donated skin from elective surgical procedures,
which was then treated with MAL only, high (75mWcm2)
or low-fluence-rate (15mWcm2) MAL-PDT and subse-
quently stained for epidermal 8oxoG (Figures 4 and 5).
MAL only and low-fluence-rate PDT were not significantly
different from control skin in area of epidermis staining for
8oxoG at any time point studied. However, high-fluence-
rate PDT caused a significant increase in epidermal 8oxoG
staining compared with control skin at t¼60minutes (% of
control 215±45, P¼0.04, n¼ 6; Figure 4). We also stained
a separate MAL-PDT-treated skin sample for cyclobutane
pyrimidine dimers, but found no increase in these direct DNA
photolesions compared with unirradiated skin. Solar-simu-
lated UV-irradiated skin, showing large numbers of cyclobu-
tane pyrimidine dimers, served as a positive control (data not
shown).
DISCUSSION
Consistent with our previous findings (Matthews and Damian,
2010), ALA-PDT was profoundly immunosuppressive in
humans, measured by both Mantoux erythema and indura-
tion, using a high-fluence-rate protocol. ALA-PDT caused a
higher level of immunosuppression (B50%) than MAL-PDT
(B35%). ALA and MAL produce the same intracellular
photosensitizer (PpIX), penetrate human skin to similar
depths and produce a similar spatial distribution of PpIX in
murine skin (de Bruijn et al., 2008). However, ALA produces
relatively greater amounts of PpIX (Juzeniene et al., 2006) and
higher levels of fluorescence with a slower time course than
MAL in human skin (Lesar et al., 2009). This, together with
greater local edema reported after ALA compared with MAL-
PDT in mice (de Bruijn et al., 2008) and the possibility of
different microscopic PpIX distributions following ALA and
MAL application to human skin, could explain the greater
immunosuppression observed after ALA-PDT in our study.
We examined normal skin, but intralesional variations in
PpIX distribution within tumors could also influence the
immune effect of PDT (de Haas et al., 2008).
ALA/MAL-PDT using our protocol impaired local immu-
nity to existing antigens (recall immunity), and could thus
impair local antitumor immunity and tumor eradication. The
effects of PDT on the development of immunity to new tumor
antigens (primary immunity) are unknown. In our studies,
immunosuppression was evident 6 days after PDT; however,
it is unknown how long this effect persists in humans. In
clinical practice, skin cancers receive ALA/MAL-PDT on two
occasions 1 week apart (Morton et al., 2008), suggesting
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Figure 4. Human skin samples (duplicates from three volunteers) were
treated with methylaminolaevulinate (MAL) only, or low-fluence
(15mWcm2) or high-fluence (75mWcm2) -MAL-photodynamic therapy.
Staining for oxidative DNA photolesions (8-hydroxy-20-deoxyguanosine) was
performed at various time points up to 2 hours to assess DNA repair as well as
damage. The percentage of epidermal area positively staining for 8-oxo at
each treatment time point was compared with untreated control skin
(unpaired two-tailed Student’s t-test, Bonferroni correction).
Figure 5. Human skin (bar¼ 100lm) was stained for 8-hydroxy-20-
deoxyguanosine. Control (untreated) skin showed low-level baseline staining
consistent with oxidative damage resulting from normal cellular metabolism
(a). Methylaminolaevulinate (MAL)-photodynamic therapy (PDT)-treated skin
using a high-fluence rate of 75mWcm2, total light dose 37 J cm2,
t¼60minutes following irradiation showed significantly higher levels of
oxidative DNA damage (b) compared with MAL-PDT-treated skin using a
low-fluence rate (c, 15mWcm2).
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immune suppression for at least 2 weeks, but possibly longer
given that PDT immunosuppression persists for at least
28 days in mice (Gollnick et al., 2001).
We found significant, dose responsive immune suppres-
sion with MAL-PDT delivered at 75mWcm2, which was
completely prevented by simply lowering the fluence rate
to deliver an identical total dose five times more slowly.
An intermediate fluence rate of 45mWcm2, a more
practical option requiring irradiation of only an additional
5minutes beyond current clinical recommendations, also did
not cause immunosuppression.
The putative central mechanism of PDT is generation of
reactive oxygen species (ROS) by irradiation of a photo-
sensitizer. PDT-induced ROS can then react with a range of
cellular targets, including cell membrane lipids and mito-
chondria as well as DNA. Irradiation with lower light doses
can alter cell signalling and cytokine and receptor expression
in the absence of cell death, suggesting that there are different
dose responses for these ROS effects (Calzavara-Pinton et al.,
2007). In human fibroblasts treated with ALA-PDT, 70–95%
of cell kill occurred without detectable DNA damage,
suggesting that mitochondrial damage, which we did not
directly examine, is also a key mechanism of cell death
(Haylett et al., 2003).
In normal human skin, we found less oxidative DNA
damage after low-fluence-rate MAL-PDT, although the effect of
reduced fluence rate on DNA damage in tumor cells is
unknown. ALA-based photosensitizers are more readily taken
up by tumors than by normal skin, with a 10-fold increase in
PpIX production in dysplastic or malignant lesions (Fritsch
et al., 2000). It is thus possible that low-fluence-rate PDT might
maintain efficacy of tumor kill by more selectively damaging
tumor DNA, causing other ROS effects such as cytokine
triggering and mitochondrial damage (Hilf, 2007) and inducing
tumor cell apoptosis (Singh et al., 2010). We examined only
total DNA and it remains possible that our low-fluence rate
may not have spared oxidative damage to mitochondria.
Despite the possibility that reduced oxidative DNA
damage, as we observed here, might impair efficacy, studies
using low-fluence-rate protocols have so far demonstrated
comparable tumor clearance rates when compared with
high–fluence-rate regimens in actinic keratoses treated with
ALA and 580–650nm or 580–690 nm light sources (Ericson
et al., 2004) and in superficial BCCs treated with ALA and
narrowband 633nm light (Cottrell et al., 2008). This implies
that high-fluence rates might not be required for efficacy.
In BCCs, photodynamic efficiency (loss of light absorbance
as photosenstizer is used in the photodynamic process)
decreased with increased fluence rate; 20mWcm2 of
narrowband red light was most efficient (Cottrell et al.,
2008). A 635 nm red light source was as effective in the
treatment of superficial BCCs at 12.6 J cm2, delivered at
7mWcm2 over 30minutes, as standard treatment (37 J cm2
over 8minutes; i.e., 75mWcm2; Langmack et al., 2001).
There is a suggestion that low-irradiance ambulatory ALA-
PDT (12mWcm2) may also be effective (Moseley et al.,
2006). Similarly, high clearance rates for actinic keratoses
were reported with lower fluence rates (30mWcm2; Ericson
et al., 2004) or even irradiation using low-intensity Copenha-
gen sunlight (Wiegell et al., 2008). Higher numbers of
neutrophils, greater inflammation, and greater expansion of
tumor-specific T cells are seen after low-irradiance, low-dose
systemic PDT compared with a high-irradiance, high-dose
regimen in mice (Kousis et al., 2007). Fractionation of
irradiation has also been suggested to improve the efficacy
of topical ALA-PDT for superficial BCC (de Haas et al., 2006),
with suggestion that neutrophils induced by systemic
PDT may be key mediators of anti-tumor immunity (Kousis
et al., 2007) and anti-tumor efficacy (de Bruijn et al., 2006) in
this setting. The role and fluence rate-dependence of
neutrophil infiltration in topical ALA/MAL-PDT in humans
is unknown.
Ultraviolet radiation induces 8oxoG photolesions that are
products of oxidative damage, and are highly mutagenic if
left unrepaired (Kozmin et al., 2005). We found that high but
not low-fluence-rate MAL-PDT induced these photolesions.
UV-induced cyclobutane pyrimidine dimers are a key trigger
of UV-induced immunosuppression (Kuchel et al., 2005)
and it has been suggested that 8oxoG may have similar
effects. Inhibition of ROS-mediated damage, such as
8oxoG, prevents immunosuppression (Yao et al., 2009).
More recently it has been shown that UV-induced platelet
activating factor and cis-urocanic acid both induce 8oxoG
formation and cause immunosuppression, whereas inhibition
of these mediators reduced 8oxoG and immunosuppression
(Sreevidya et al., 2010). It is not known yet whether enhanced
repair of 8oxoG helps to prevent immunosuppression, but
topical application of the 8oxoG repair enzyme 8 oxogua-
nosine DNA glycosylase reduced tumor size and progression
in photoinduced tumor models (Wulff et al., 2008). Hence,
ROS-mediated damage, such as 8oxoG, is a key molecular
mechanism causing immunosuppression (Halliday, 2010). In
our study, the immunosuppression following high-fluence-
rate ALA/MAL-PDT may reflect oxidative DNA damage,
which at lower fluence rates is no greater than the expected
baseline level of oxidative damage that results from normal
cellular metabolism (Javeri et al., 2008). Additional studies
are now indicated to better evaluate the cellular and
cytochemical changes involved in PDT-induced immunomo-
dulation, to improve PDT efficacy in skin cancer, but possibly
also to use immune suppressive effects in the treatment of
immune-mediated disorders such as psoriasis (Morton et al.,
2008).
Topical PDT at high but not low-fluence rates causes both
immunosuppression and induction of oxidative DNA photo-
lesions in human skin. As both immunosuppression and DNA
damage are recognized tumor promoters, this suggests that
simply irradiating more slowly may have the potential to
reduce tumor recurrence and boost cure rates. Further studies
are now urgently needed to assess the role of PDT-
immunosuppression in PDT treatment failures and the
mechanisms of cell toxicity following low-fluence-rate PDT.
Using randomized controlled trials, we then need to
determine the comparative efficacy of low irradiance rate
PDT, so that we can establish and recommend to clinicians
the optimal PDT protocol.
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MATERIALS AND METHODS
Mantoux testing
We recruited healthy Mantoux positive hospital staff and students,
who had previously been vaccinated with Bacille Calmette-Guerin.
Volunteers were not taking immunosuppressive or photosensitizing
medications and were asked to avoid sun exposure for 4 weeks
before and throughout the study, as even small UV exposures can
suppress skin immunity (Damian and Halliday, 2002). Approval for
these studies was provided by the Sydney South West Area Health
Service and University of Sydney Ethics Committees and all
participants provided written informed consent. All experiments
were performed in accordance with the precepts established by the
Helsinki Declaration.
Volunteers were initially Mantoux tested with three graded doses
of tuberculin PPD (Tubersol; Sanofi-Pasteur, Toronto, ON, Canada)
to determine both Mantoux positivity and the appropriate PPD dose
to elicit a Mantoux diameter of B8mm. PPD was diluted with
normal saline to a volume of 0.1ml and injected intradermally on
the lateral lower back with 31-gauge needles. Mantoux reactions
were assessed 72 hours later using the ‘pen method’, which
measures Mantoux diameter of induration in two perpendicular
planes (Bouros et al., 1991). The EI at each Mantoux site and at
adjacent skin was measured in triplicate using a portable reflectance
meter (Dia-stron, Andover, UK). The EI of adjacent skin was then
subtracted from the EI overlying Mantoux reactions to determine
Mantoux-induced erythema, and to adjust for any PDT-induced
erythema (Damian and Halliday, 2002).
Photodynamic therapy
Templates were created on each side of the lower back using
Comfeel Plus Ulcer Dressing (Coloplast A/S, 3050 Humlebaek,
Denmark) to create discrete 3 2 cm areas separated by 1 cm.
Treatment allocation at each square was randomized based on order
of study entry, with a mirror image of treatment site allocation on the
contralateral back. In all, 40mg cm2 of the photosensitizers 20%
ALA in white soft paraffin (Biosynth AG, Staad, Switzerland) and
MAL 16% cream (Metvix: Galderma, Belrose, New South Wales,
Australia) or vehicle (emulsifying ointment) were applied to the
various sites, which were then occluded for 3 hours under Tegaderm
dressings (3M Healthcare, St Paul, MN) and light protected with
aluminum foil. The creams were then removed and test sites exposed
to varied fluence rates and total light doses from an Aktilite CL128
LED array (PhotoCure, ASA, Oslo, Norway). The light source emitted
narrowband red light with a peak of 632 nm as measured at 1 nm
intervals with an Optronics OL754 spectroradiometer (Optronics,
Orlando, FL) calibrated against standard lamps. Irradiance was
monitored daily with an IL1700 broadband radiometer (International
Light Technologies, Peabody, MA), calibrated against the spectro-
radiometer. After irradiation, all treatment sites remained light
protected with aluminum foil for a further 24 hours.
Measurement of immunosuppression and data analysis
At 72 hours after irradiation each of the treatment and control sites
were injected with PPD, and the resulting Mantoux reactions
quantitated by diameter and erythema measurements 72 hours
thereafter. Immunosuppression was calculated as the difference
between control site (no photosensistizer, no light) and treatment site
Mantoux reactions. Results are shown as mean±SEM; significance
was determined by Bonferroni corrected paired Student’s t-tests with
Po0.05 considered significant.
Measurement of PDT-induced DNA photolesions
Three healthy adults undergoing abdominoplasty (n¼ 2) or breast
reduction (n¼ 1) consented for their excised skin to be used in the
study. Skin was collected in normal saline, trimmed of excess fat,
washed in chlorhexidine, rinsed with phosphate-buffered saline
(Invitrogen, Calsbad, CA), and cut into 3 cm squares, which received
MAL only (no light), low-fluence-rate MAL-PDT (15mWcm2),
high-fluence-rate MAL-PDT (75mWcm2), or no treatment
(control). MAL (16%, 40mg cm2) was applied and occluded with
Tegaderm. The skin was then placed into separate petri dishes
containing RPMI-1640 medium (Sigma-Aldrich, St Louis, MO)
supplemented with 10% fetal bovine serum and 100Uml1
penicillin, 0.1mgml1 streptomycin, and 250ngml1 amphotericin
B (Sigma-Aldrich). Petri dishes were light protected with aluminum
foil and incubated for 3 hours at 37 1C in 5% CO2 in air. MAL was
removed using phosphate-buffered saline and specimens were
rinsed twice in phosphate-buffered saline and cut into 5mm squares.
The two PDT groups were then exposed to 37 J cm2 of red light
(Aktilite) with a fluence rate of 15 or 75mWcm2. Duplicate skin
pieces were collected immediately or after various times of incubation
in the media described above, snap frozen in OCT (Tissue-Tek, Sakura,
Zoeterwoude, the Netherlands) and stored at 701C. Frozen sections
(6-mm thick) were stained by immunohistochemistry using mouse
monoclonal anti-8oxoG antibody (Trevigen, Gaithersburg, MD), as we
have described previously (Javeri et al., 2008). Separate pieces of skin
were treated with MAL-PDT (37 J cm2, 75mWcm2) or solar-
simulated UV (4 J cm2), and stained for cyclobutane pyrimidine
dimers (Kamiya Biomedical, Seattle, WA).
The area of positively stained epidermis was determined by
image analysis (ImageJ, Wayne Rasband, National Institutes of
Health). The average percentage staining for each treatment group at
the five time points was then calculated and compared with the
average of the control by Student’s unpaired t-tests (Boneferroni
correction; Po0.05 considered significant).
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